ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2019

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data.

Khyatiben Rana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.